Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables - Other: 2016-2024

Historic Receivables - Other for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2024 value amounting to $23.5 million.

  • Tg Therapeutics' Receivables - Other rose 298.31% to $23.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.5 million, marking a year-over-year increase of 298.31%. This contributed to the annual value of $23.5 million for FY2024, which is 298.31% up from last year.
  • As of Q4 2024, Tg Therapeutics' Receivables - Other stood at $23.5 million, which was up 261.54% from $6.5 million recorded in Q1 2024.
  • Tg Therapeutics' Receivables - Other's 5-year high stood at $23.5 million during Q4 2024, with a 5-year trough of $5.9 million in Q4 2023.
  • Moreover, its 2-year median value for Receivables - Other was $6.7 million (2023), whereas its average is $10.7 million.
  • Data for Tg Therapeutics' Receivables - Other shows a peak YoY surged of 298.31% (in 2024) over the last 5 years.
  • Tg Therapeutics' Receivables - Other (Quarterly) stood at $5.9 million in 2023, then soared by 298.31% to $23.5 million in 2024.
  • Its Receivables - Other was $23.5 million in Q4 2024, compared to $6.5 million in Q1 2024 and $5.9 million in Q4 2023.